PolyPid (PYPD) reported a third-quarter loss of $0.24 per share on no revenue, far below a consensus that called for a $0.46 profit on $30.0 million in revenue. That is a 152.2% earnings miss and a 100.0% revenue shortfall. The size of the miss matters less than its cause. Consensus appears to have assumed that the $30 million in Azurity upfront and milestone payments would flow through the income statement. Instead, the balance sheet shows $30.0 million sitting in non-current deferred revenue, up from $2.5 million at year-end. The cash is real: $15 million arrived at the July signing, and a $15 million receivable tied to NDA acceptance was collected in October. It has simply not been recognized as revenue. Year over year, earnings improved 35.1% as the net loss narrowed to $5.8 million from $7.5 million.

The quality of that improvement deserves scrutiny. The narrower loss leaned on $2.5 million of other income, which came from recognizing previously deferred ADVANZ revenue when that European agreement was terminated on September 30. Excluding that one-time item, operating expenses were roughly $8.5 million, up from about $7.5 million a year ago. The main driver was research and development, which rose to $6.5 million from $5.3 million because of NDA work and commercial-readiness spending. G&A fell to $1.5 million, but mostly because non-cash performance-option expense dropped after earlier vesting. The per-share comparison also benefits from a larger share base: weighted shares were about 23.7 million versus 20.1 million. The underlying cost base is growing, not shrinking, and that is reasonable for a company preparing for launch and widening its pipeline.

The call showed steady regulatory progress rather than any change in financial guidance:

• **FDA review:** Labeling discussions for D-PLEX100 are underway, and management said all scheduled FDA interactions remain aligned with the November 28 PDUFA date. That is a clear step forward from the second quarter, when the NDA had only just been accepted under Priority Review.
• **Europe:** The EU marketing application was filed on September 14, meeting the stated timeline, and the EMA has validated it. A decision is expected in the second half of 2027.
• **Label expansion:** The plan is now more concrete. FDA engagement on broader abdominal surgery, about 4 million U.S. procedures a year, begins this quarter and is funded by Azurity. That framing differs from the second quarter, when CABG, orthopedic and breast procedures were the emphasis.
• **Pipeline:** The new PD01B program for diabetic foot infections adds a second Kynatrix-based asset, with a pre-IND meeting and first-in-human study targeted for the second half of 2027.

The risk side is where bears have legitimate ammunition. Management declined to confirm whether the FDA's pre-approval manufacturing inspection is complete, saying only that steps were "set or done." Days before a PDUFA date, that is a notable gap. Even with approval, the launch was described as a gradual, account-by-account hospital formulary process stretching over several months. NTAP reimbursement would not take effect until October 2027 even if granted, and Azurity controls pricing and will not disclose it before launch. Regaining European rights gives PolyPid strategic control, but it also means Europe currently has no commercial partner. Azurity's split of the more than $290 million in potential milestones remains undisclosed.

The balance sheet is much improved. Cash and deposits rose to $15.5 million from $6.6 million at the end of June, before counting the October milestone. Management reaffirmed a runway into 2028, compared with "into the second half of 2026" at the start of the year. Shareholders' equity is thin at $3.9 million, but that largely reflects the $30 million parked in deferred revenue rather than cash strain.

The market had already moved ahead of the event. Shares are up 37.5% since the open following the August report, closing at $6.31. That leaves the stock 32% above its 200-day moving average and only 2.6% below the 52-week high of $6.48 set on November 9. Price and momentum trends are positive, though sequential growth is negative, consistent with a company that has no product revenue yet. Investor sentiment stayed positive but weakened, slipping from 0.20 to 0.10. Enthusiasm appears to have cooled even as the stock climbed, which fits a run-up into a binary regulatory event.

The bottom line is that the headline miss mostly reflects where the Azurity money sits on the balance sheet. It says little about how the business is performing. The fundamental story is entirely about execution on the November 28 PDUFA. PolyPid enters that decision with more cash, full European rights and a broader pipeline. It also carries open questions on inspection status, launch pace and pricing. With shares near their highs and sentiment fading, investors are positioned for approval, and the period after approval will test how patient they are with a slow commercial ramp.